Clinical Characteristics and Disease Burden of Patients with Moderate-to-Severe Generalized Pustular Psoriasis Flares in Taiwan
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Clinical Characteristics and Disease Burden of Patients with Moderate-to-Severe Generalized Pustular Psoriasis Flares in Taiwan ; volume:14 ; number:8 ; day:30 ; month:7 ; year:2024 ; pages:2261-2275 ; date:8.2024
Dermatology and therapy ; 14, Heft 8 (30.7.2024), 2261-2275, 8.2024
- Urheber
-
Lu, Chun-Wei
Tseng, Chien-Yu
Wang, Chuang-Wei
Lin, Shang-Hung
Chen, Chun-Bing
Hui, Rosaline Chung-Yee
Chi, Ching-Chi
Huang, Yu-Huei
Lee, Chih-Hung
Lin, Fang-Ju
Chung, Wen-Hung
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-024-01228-7
- URN
-
urn:nbn:de:101:1-2411052107395.375307992572
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lu, Chun-Wei
- Tseng, Chien-Yu
- Wang, Chuang-Wei
- Lin, Shang-Hung
- Chen, Chun-Bing
- Hui, Rosaline Chung-Yee
- Chi, Ching-Chi
- Huang, Yu-Huei
- Lee, Chih-Hung
- Lin, Fang-Ju
- Chung, Wen-Hung
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations